7-OH (7-Hydroxymitragynine): Dependence, Withdrawal, and Recovery Support

7-OH (7-hydroxymitragynine) is not kratom. It is an opioid that occurs in trace amounts in the kratom leaf, isolated or made in a lab and pressed into tablets, gummies, and shots at doses the plant never delivers. The FDA puts it plainly: "7-OH is an opioid that can be more potent than morphine" (FDA, July 29, 2025). Most people we talk to who are struggling with it started on plain kratom, moved to 7-OH because it worked better, and found within weeks that they could not go a few hours without it. This page covers what it is, what withdrawal and treatment look like, where the law stands, and how support at home fits in. The research is thin, and we say so where it matters.

What 7-OH is and how it differs from kratom

Kratom leaf contains dozens of alkaloids. The main one is mitragynine. A second one, 7-hydroxymitragynine, "comprises less than 2% of the total alkaloid content in natural kratom leaves" and "demonstrates substantially greater mu-opioid receptor potency than kratom's primary alkaloid constituent mitragynine, as well as other classical opioids such as morphine" (FDA and Kratom). With leaf kratom, the body converts some mitragynine into 7-OH slowly, and NIDA notes that this slow conversion "limits mitragynine's effects on breathing" (NIDA). That built-in speed limit is why leaf kratom carries a different risk than a straight opioid.

7-OH products remove the speed limit. According to the DEA, 7-OH "can be synthesized from mitragynine through a one-step chemical reaction," and marketed products have ranged "from 1 mg to 700 mg in a single dose or serving" (DEA, Federal Register, 2026). The FDA Commissioner's letter to clinicians cites a Journal of Medicinal Chemistry study that found 7-OH "13 times more potent than morphine" (FDA letter to health care professionals, 2025). The DEA notes that "isolated or semi-synthetically derived formulations deliver unattenuated, high-potency effects" that the leaf's mix of alkaloids would otherwise soften (DEA). In plain language, a 7-OH tablet is a concentrated opioid with the brakes taken off.

You will see it sold as 7-OH, 7-OHMZ, 7-hydroxy, "7," or "enhanced kratom," in tablets, gummies, drink mixes, shots, capsules, and dissolvable strips, online and at gas stations, smoke shops, and convenience stores (FDA consumer update; DEA, 2026). The FDA's position is that 7-OH "is not a lawful dietary supplement, food additive, or ingredient in any approved drug," and in July 2025 it sent warning letters to seven companies selling it with pain and anxiety claims (FDA, July 15, 2025). What is in a given tablet, and how much, is not something you can know from the package.

How people slide from kratom to 7-OH

Almost nobody starts with 7-OH. Someone uses kratom powder for pain, energy, anxiety, or to get off a prescription opioid. The dose creeps up and the effect flattens. Then a clerk at the smoke shop suggests the tablets, and one small pill does what a heaping spoonful of powder used to do. The DEA's review of user reports found the same pattern: "Users consistently report transition from traditional kratom leaf to 7-hydroxymitragynine tablets," and "a dominant theme is the short-lived nature of the 7-hydroxymitragynine high. Users report the urge to redose frequently" (DEA, 2026).

That short high is the trap. In a human pharmacokinetic study of kratom extract, 7-OH's half-life after a single dose was roughly 2.4 to 6.0 hours, compared with 13.5 to 54.7 hours for mitragynine (Huestis et al., J Anal Toxicol, 2026). A drug that leaves the body that fast teaches the brain to want it again by lunch. Tolerance builds and the gap between "I feel fine" and "I feel sick" shrinks to a few hours. The DEA's preclinical summary says 7-OH "carries a high abuse potential with safety risks, including tolerance, dependence, and respiratory depression, which are comparable to those of classic opioid analgesics" (DEA, 2026). Members tell us they never thought of it as an opioid habit, because they bought it next to the energy drinks.

Signs 7-OH has become a problem

The signs are the signs of opioid dependence, in a gas station wrapper. Needing a tablet first thing in the morning to feel normal. Taking it every few hours and carrying a supply everywhere. Spending far more than planned. Feeling sick, sweaty, anxious, and achy when a dose is late, then fine within minutes of taking one. Trying to cut back and failing. Describing the tablets to family as "just kratom" or "a supplement." Poison centers logged 165 exposure cases involving 7-OH between the start of 2025 and the end of July that year, and among people who had taken 7-OH alone, 35 percent had serious health effects (DEA, 2026).

Is it dangerous to stop 7-OH suddenly?

Opioid withdrawal is rarely fatal on its own, and 7-OH appears to behave like an opioid in this respect. What makes stopping dangerous is what comes after. A person who has been off 7-OH for a week or two has lost tolerance, and a return to the old dose, or a switch to a different opioid to make the sickness stop, can cause respiratory depression. That is the moment we worry about most. Heavy 7-OH withdrawal is also not something to white-knuckle in a bedroom; seizures, vomiting that will not stop, or confusion mean an emergency room visit.

7-OH withdrawal timeline

There are no controlled studies of 7-OH withdrawal in humans. What follows is drawn from the FDA's symptom list, published case reports, the compound's short half-life, and what our members describe. Your timeline will depend on dose, frequency, duration, and whether other substances are involved.

First 4 to 12 hours

Because 7-OH clears quickly, early symptoms can begin within hours of the last dose. The FDA describes 7-OH withdrawal as including "restlessness, body aches, fatigue, irritability and cold sweats" (FDA). In one published case, a man using about 1,000 mg of 7-OH a day had a Clinical Opiate Withdrawal Scale score of 14 about five hours after admission, climbing into the low 20s over the following hours (Held and Varicat, Prim Care Companion CNS Disord, 2026).

Days 1 to 3

This is usually the worst stretch. Diarrhea, stomach cramps, sweating, chills, muscle and bone aches, insomnia, and a restlessness that makes it hard to sit still. The fix is a short drive away, which is why people so often give up on day two.

Days 4 to 10

Physical symptoms ease for most people. Sleep stays poor. Mood is flat or low, and the anxiety that kratom or 7-OH was quietly managing tends to come back in full.

Weeks 2 and beyond

Cravings become situational: the gas station on the way home, a stressful shift, a bad night. NIDA characterizes withdrawal from regular leaf kratom as "mild to moderate" (NIDA). In our experience, withdrawal from heavy 7-OH use is closer to what people describe coming off prescription opioids, which fits how the drug behaves.

How treatment for 7-OH dependence works

There is no FDA-approved medication for 7-OH dependence and no treatment guideline written for it. In practice, clinicians treat it as an opioid use disorder and reach for the tools they already have. In the case above, a starting dose of 2 mg of buprenorphine-naloxone did nothing, the patient received a total of 40 mg in the first 24 hours, and he stabilized on 32 mg a day in divided doses (Held and Varicat, 2026). The authors' point, which we echo, is that clinicians need to ask specifically about 7-OH, because patients often say "kratom" and the doses can call for more medication than a standard protocol expects. A single case is not a dosing guide; it is a signal that this needs a prescriber.

Some people transition onto buprenorphine and stay on it for months or longer, as with other opioids. Some do a supervised taper with medications for sleep, stomach symptoms, and anxiety along the way. Some need a short inpatient stay, especially at very high doses or when alcohol or benzodiazepines are also involved. Whatever the medical route, the months after decide the outcome: whether someone is checking in, whether the route home changes, whether there is a plan for the 3 p.m. slump a tablet used to fix.

7-OH with alcohol, benzodiazepines, or other opioids

7-OH slows breathing the way other opioids do. NIDA states that "in laboratory models, 7-OH can cause respiratory depression that is reversed by naloxone" (NIDA). Add alcohol, Xanax, sleep medication, or another opioid and the risk multiplies. As of February 2026 the FDA's adverse event database held 86 reports involving 7-OH, 79 of them serious and 9 fatal (DEA, 2026). If someone in your house uses 7-OH, keep naloxone within reach; Texas health officials advise providers to "administer naloxone for reversal of respiratory depression" (Texas DSHS). If someone is unresponsive, call 911, give naloxone, and stay with them.

Drug testing for 7-OH

Standard drug panels do not look for 7-OH or mitragynine. In the case above, the patient's urine drug screen was negative for opioids despite about 1,000 mg of 7-OH a day (Held and Varicat, 2026). Detecting it requires a specialized kratom alkaloid test, and because 7-OH clears within hours, labs generally look for mitragynine as well, which lingers far longer (Huestis et al., 2026). We have not found a published study of oral fluid detection windows for concentrated 7-OH products, so we will not quote one.

Our members use saliva-based toxicology screening that is assigned at random through the week. You do not choose whether you test; you choose who sees the results. Because 7-OH needs its own assay, the first thing we do with a member whose concern is 7-OH is make sure the screening covers kratom alkaloids. For someone coming off 7-OH, that usually means the prescriber and, if the member wants, a spouse or parent. We explain the details in our guide to how sobriety monitoring works.

Where the law stands

On July 29, 2025, the FDA recommended that 7-OH be scheduled under the Controlled Substances Act (FDA, 2025). On July 1, 2026, the DEA announced its intent to temporarily place concentrated 7-OH, plus three related synthetic compounds, in Schedule I (DEA, 2026). The notice, published July 6, 2026, sets the threshold at 0.050 percent 7-OH by weight, or more than 1.00 mg per tablet or serving, with an order that could take effect on or after August 5, 2026 and last two years (Federal Register). The order covering the three related compounds took effect August 26, 2026 (Federal Register). The FDA has said the DEA actions "are not intended to apply to natural kratom leaf containing only naturally occurring trace levels of 7-OH" (FDA, Hiding in Plain Sight). Several states have their own bans, so check the DEA and your state for the current status. For someone who is dependent, the practical point is that supply may vanish from shelves suddenly, and a forced cold-turkey stop is not how anyone should come off this.

How recovery from 7-OH works with Accountable

We are not a detox and we do not prescribe; decisions like whether buprenorphine makes sense belong to a doctor. What we provide is the long stretch after the medical part: a peer recovery coach who has been where you are, and a way for the people who love you to know how things are actually going. It usually runs in three stages.

1. Get the full picture

In the first sessions your coach maps what is really going on: how many tablets a day, how many hours before you feel sick, what happened the last time you tried to stop, and whether alcohol, benzodiazepines, or other opioids are in the mix. If you do not have a prescriber, we help you find one who knows what 7-OH is, and with your permission we coordinate with them.

2. Build a plan that fits your life

7-OH is sold on the way to everything. Your coach helps you plan around the real map: which gas station to stop using, what to do at the hour the craving hits hardest, who to text before you walk into a smoke shop. Daily peer group meetings give you people who understand this was not "just a supplement," and the weekly family Zoom group gives your family their own place for support.

3. Weekly check-ins through the long stretch

Your coach shows up every week, and the random saliva screening, set up to include kratom alkaloids, turns "I think he's doing okay" into a shared record that you control. When a slip happens, and with a drug this easy to buy it often does early, we treat it as information: the plan changes and the support goes up. Every coach at Accountable has their own recovery behind them.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

What is 7-hydroxymitragynine (7-OH)?

It is an opioid alkaloid that occurs in trace amounts in kratom leaf, less than 2 percent of the plant's alkaloid content (FDA). Products sold as 7-OH contain it in concentrated, often synthetically produced form, at doses far above anything in the leaf. The FDA calls it "a potent opioid that is an emerging public health threat" (FDA).

Is 7-OH withdrawal different from kratom withdrawal?

Yes, in our experience. NIDA describes leaf kratom withdrawal as "mild to moderate" (NIDA). Withdrawal from heavy 7-OH use starts faster, because the drug clears within hours, and tends to feel like withdrawal from a prescription opioid: sweats, aches, stomach symptoms, restlessness, and intense craving. There are no controlled studies yet, so this is based on case reports and what members describe.

Is there a medication for 7-OH addiction?

Nothing is FDA-approved for it. Because 7-OH acts on the same opioid receptors as other opioids, clinicians have used buprenorphine-naloxone to manage withdrawal and as ongoing treatment, and case reports describe patients needing higher doses than usual (Held and Varicat, 2026). Talk to an addiction medicine prescriber and tell them exactly what you were taking and how much.

Is 7-OH legal?

It is changing. The FDA has said 7-OH is not a lawful supplement or food ingredient, and in July 2026 the DEA announced its intent to place concentrated 7-OH in Schedule I on a temporary basis (DEA). Some states already ban it. Check current federal and state rules rather than relying on a store still selling it.

Does 7-OH show up on a drug test?

Not on a standard panel. A routine opioid screen does not detect 7-OH or mitragynine, and in one published case a urine screen was negative despite very heavy daily use (Held and Varicat, 2026). Detecting it takes a specialized kratom alkaloid test. Our screening can include it when 7-OH is the concern.

Sources

• U.S. Food and Drug Administration. FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers. Press release, July 29, 2025.

• U.S. Food and Drug Administration. FDA Issues Warning Letters to Firms Marketing Products Containing 7-Hydroxymitragynine. Press release, July 15, 2025.

• U.S. Food and Drug Administration. Letter from the FDA Commissioner to health care professionals on concentrated 7-OH opioid products, July 29, 2025.

• U.S. Food and Drug Administration. Products Containing 7-OH Can Cause Serious Harm. Consumer update, July 29, 2025.

• U.S. Food and Drug Administration. Hiding in Plain Sight: 7-OH Products. Public health focus page, updated July 13, 2026.

• U.S. Food and Drug Administration. FDA and Kratom. Public health focus page, current as of December 2, 2025.

• National Institute on Drug Abuse. Kratom. Research topic page, updated March 11, 2026.

• Drug Enforcement Administration. DEA to Temporarily Schedule 7-OH and Related Substances to Protect Public Safety. Press release, July 1, 2026.

• Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine Above a Specified Threshold in Schedule I. Notice of intent, Federal Register, July 6, 2026.

• Drug Enforcement Administration. Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I. Temporary scheduling order, Federal Register, August 26, 2026.

• Texas Department of State Health Services. Serious Illnesses Associated with 7-OH Use. Health alert, September 2, 2025.

• Held JT, Varicat FP. 7-Hydroxymitragynine Withdrawal Treated With Buprenorphine-Naloxone. Primary Care Companion for CNS Disorders. 2026;28(4):26cr04232.

• Huestis MA, Brett MA, Bothmer J, Henningfield JE, Swift S. Mitragynine and 7-hydroxy-mitragynine plasma pharmacokinetics in humans after single and 15 multiple oral kratom extract doses. Journal of Analytical Toxicology. 2026;50(6):bkag042.